Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2019 | 0.1318 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.3155 | 0.2553 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2019 | 0.1318 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.0694 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.0808 | 0.2561 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.0808 | 0.2561 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.0694 | 0.22 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.0694 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0808 | 0.2561 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0694 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.2019 | 0.1318 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0694 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3155 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.2019 | 0.1318 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.2019 | 0.64 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.2019 | 0.1318 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.0694 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.2019 | 0.1318 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2019 | 0.1318 |
Onchocerca volvulus | 0.0033 | 0.0808 | 0.5 | |
Brugia malayi | hypothetical protein | 0.002 | 0.0118 | 0.0373 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0776 | 0.246 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3155 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0694 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.0808 | 0.2561 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3155 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3155 | 0.2553 |
Onchocerca volvulus | 0.0033 | 0.0808 | 0.5 | |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3155 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3155 | 1 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.0808 | 0.2561 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.3155 | 0.2553 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3155 | 0.2553 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3155 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3155 | 0.2553 |
Brugia malayi | hypothetical protein | 0.003 | 0.0694 | 0.22 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3155 | 0.2553 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0694 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.2019 | 0.64 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0694 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3155 | 0.2553 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0891 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.5481 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 9.2 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.